Dr. Tripathy Discusses Impact of T-DM1 in HER2+ Breast Cancer

Video

In Partnership With:

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-positive breast cancer.

The results from the KATHERINE trial presented at the 2018 San Antonio Breast Cancer Symposium are notable because they essentially impact practice immediately, says Tripathy. Treatment with T-DM1 nearly halved the number of recurrences in patients who had residual disease from standard neoadjuvant therapy. Although some patients had to come off therapy early due to adverse events, T-DM1 seemed to be well-tolerated overall, Tripathy adds.

Results from the phase III trial showed that the 3-year invasive disease-free survival (iDFS) rate was 88.3% with T-DM1 versus 77.0% with trastuzumab. The iDFS benefit with T-DM1 was upheld across key patient subgroups, according to data published in the New England Journal of Medicine.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD